In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study: Inhibitors in mild and moderate hemophilia A
Twenty-five percent of new anti-factor VIII (FVIII) antibodies (inhibitors) that complicate hemophilia A occur in those with mild and moderate disease. Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined
